1. Aoki, M. (2001). Toward a comparative institutional analysis.Cambridge, MIT Press.
2. Graf, J. (2014). The effects of rebate contracts on the health care system. The European Journal of Health Economics, 15(5), 477–487.
3. Hodaka, E. (2012). Sinyaku sousyutu Kasan to ryuutuu toumei ka ato ga nai orosi keiei [The price maintenance premium and distribution transparency: Wholesaler management with no postponement]. Pharmaceutical Distribution Frontier Years Book ’12-’13. Elsevier Japan.
4. The Japan Fair Trade Commission. (2006). Iryou you iyakuhin no ryuutuu zittai ni kan suru tyousa houkokusyo [Investigation report on the actual conditions of distribution of ethical drugs]. https://www.jftc.go.jp/houdou/pressrelease/cyosa/cyosa-ryutsu/h18/06092702_files/06092702-hontai.pdf Accessed 10 January 2020
5. Kakani, P., Chernew, M., & Chandra, A. (2020). Rebates in the pharmaceutical industry: Evidence from medicines sold in retail pharmacies in the U.S. NBER (National Bureau of Economic Research) Working Paper No.26846.